LRRK2 kinase inhibitors induce a reversible effect in the lungs of non-human primates with no measurable pulmonary deficits
Marco A.S. Baptista, Kalpana Merchant, Ted Barrett, Diane K. Bryce, Michael Ellis, Anthony A. Estrada, Matthew J. Fell, Brian K. Fiske, Reina N. Fuji, Paul Galatsis, Anastasia G. Henry, Sue Hill, Warren Hirst, Christopher Houle, Matthew E. Kennedy, , Todd B. Sherer
This study evaluates the lung effects of LRRK2 kinase inhibitors in non-human primates, finding reversible histopathological changes without pulmonary function deficits.
bioRxiv · Aug 15, 2018 · PreprintPharmacology & Toxicology